The world’s population is aging at an unprecedented pace. According to WHO’s October 2024 report, the number of people aged 60 and older surpassed children under five for the first time in 2020. By ...

AbbVie and Xilio Therapeutics have announced a partnership worth over $2.1bn to develop tumour-activated, antibody-based immunotherapies. The collaboration and option-to-licence agreement will include ...

Novartis NVS and AbbVie ABBV announced small M&A deals. The FDA approved the expanded use of Pfizer’s PFE cancer drug Adcetris and a tablet formulation of Roche’s R ...

RxTechExam and the Pennsylvania Pharmacists Association announced a strategic partnership. Roche’s $8 billion InterMune acquisition has been handed to a specialty pharmaceutical company, Cayman ...

Henry Gosebruch, Neumora’s CEO since 2023, will depart. Elsewhere, Biogen dropped two antisense drugs in a pipeline cull and ...

AbbVie has entered a partnership and option-to-license agreement with Xilio for tumour-activated, antibody-based ...

Shares in biotech group Xilio Therapeutics (XLO) surged over 125% today after it sealed a cancer-fighting deal with AbbVie ...

Ab­b­Vie and Xilio Ther­a­peu­tics are part­ner­ing to make “masked” T cell en­gagers, which they hope will be safer than cur­rent­ly avail­able op­tions.

AbbVie Inc (NYSE:ABBV) and Xilio Therapeutics, Inc. (NASDAQ:XLO) announced a collaboration and option-to-license agreement to ...

US pharma major AbbVie has announced a deal with Xilio Therapeutics, more than doubling the latter’s share price.

AbbVie (NYSE: ABBV) and Xilio Therapeutics, Inc. (NASDAQ: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with ...

The North Chicago drugmaker says it could pay Xilio Therapeutics more than $2.1 billion in a collaboration and ...